Standing up together to the shame and stigma associated with hidradenitis suppurativa

Kirby, Joslyn S.; Leiphart, P.

doi:10.1111/bjd.18707

Cited by 8 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Influence of baseline BMI may play a larger role in the development of HS in women and younger patients. Patients with HS are already subject to numerous disease‐related stigmatizations 30,31 . The authors underscore herein that findings in this study should not further stigmatize patients who are afflicted with HS.…”

Section: Discussionsupporting

confidence: 50%

“…Patients with HS are already subject to numerous disease-related stigmatizations. 30,31 The authors underscore herein that findings in this study should not further stigmatize patients who are afflicted with HS. Given the negative impact of the condition on physical activity, we acknowledge that HS may contribute to weight gain in individual cases.…”

Section: Discussionmentioning

confidence: 54%

See 1 more Smart Citation

Trends in body mass index before and after diagnosis of hidradenitis suppurativa

2021

View full text Add to dashboard Cite

Background A temporal relationship between hidradenitis suppurativa (HS) and obesity has not been established. Objectives To compare baseline body mass index (BMI) and change in BMI for patients with HS and controls before and after diagnosis. Methods We performed a retrospective case-control analysis of 1284 patients with HS and controls matched for age, sex, race and calendar year between 1 January 1999 and 9 September 2019. BMI 7 years prior to first HS diagnosis, and rate of BMI change, were compared for patients with HS and controls using linear mixed effects models. Results Baseline BMI was higher among patients with HS than controls [mean difference 3Á03 kg m −2 , 95% confidence interval (CI) 2Á44-3Á62; P < 0Á001)]. This difference was larger for women [mean difference 3Á37 kg m −2 (95% CI 2Á73-4Á01)] than men [mean difference 1Á27 kg m −2 (95% CI − 0Á20-2Á73; interaction P = 0Á01)], and for patients with HS diagnosed before age 40 years [mean difference 4Á10 kg m −2 (95% CI 3Á15-5Á06)] than those diagnosed after age 40 years [mean difference 2Á38 kg m −2 (95% CI 1Á63-3Á12; interaction P < 0Á001)]. Prior to diagnosis, average annual increase in BMI among patients with HS was slightly higher than controls. There was no statistically significant change in annual BMI among patients with HS following diagnosis. Conclusions Baseline BMI and, to a lesser extent, rate of BMI change appear to be risk factors for developing HS. The influence of BMI may play a larger role among female patients and younger patients.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 54%

Trends in body mass index before and after diagnosis of hidradenitis suppurativa

2021

View full text Add to dashboard Cite

show abstract

“…Even with access to well‐trained and knowledgeable clinical providers, HS can lead individuals to feel isolated and stigmatized 53,54 . Connecting patients with resources such as advocacy groups can be significant.…”

Section: Quality Of Lifementioning

confidence: 99%

Pediatric hidradenitis suppurativa

Lee

Park

Toledo

et al. 2022

Dermatological Reviews

View full text Add to dashboard Cite

Pediatric hidradenitis suppurativa (HS) is a chronic inflammatory disorder that often occurs after puberty and can have a significant impact on quality of life and psychosocial health. Early diagnosis with carefully optimized holistic care are essential for improved outcomes in pediatric HS. In this review, we address diagnosis, epidemiology, associated comorbidities, and management of HS in the pediatric population.

show abstract

“… 1 Inflammatory lesions may progress to tunnel formation and sometimes fistulization, both of which are associated with pain, hypertrophic scarring, and possible impact on functional use of the limbs. 3 , 4 Epidemiologic studies report a varying global prevalence between 0.1 and 4% 5 , 6 , 7 ; these inconsistencies may be due to significant delays of 7–10 years between disease onset and diagnosis, 8 , 9 under‐reporting by patients due to embarrassment and shame associated with HS 10 or differences in prevalence due to ethnicity. 11 HS is a disease with a high unmet medical need that has a devastating effect on patients' quality of life (QoL).…”

Section: Introductionmentioning

confidence: 99%

“…report a varying global prevalence between 0.1 and 4% [5][6][7] ; these inconsistencies may be due to significant delays of 7-10 years between disease onset and diagnosis, 8,9 under-reporting by patients due to embarrassment and shame associated with HS 10 or differences in prevalence due to ethnicity. 11 HS is a disease with a high unmet medical need that has a devastating effect on patients' quality of life (QoL).…”

mentioning

confidence: 99%

IL‐17A is a pertinent therapeutic target for moderate‐to‐severe hidradenitis suppurativa: Combined results from a pre‐clinical and phase II proof‐of‐concept study

Kimball

Loesche

Prens³

et al. 2022

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

Standing up together to the shame and stigma associated with hidradenitis suppurativa

Abstract: Linked Article: Keary et al. Br J Dermatol 2020; 182:342–347.

Cited by 8 publications

References 10 publications

Trends in body mass index before and after diagnosis of hidradenitis suppurativa

Trends in body mass index before and after diagnosis of hidradenitis suppurativa

Pediatric hidradenitis suppurativa

IL‐17A is a pertinent therapeutic target for moderate‐to‐severe hidradenitis suppurativa: Combined results from a pre‐clinical and phase II proof‐of‐concept study

Contact Info

Product

Resources

About